Skip to main content
Premium Trial:

Request an Annual Quote

Opko Licenses Kallikrein Proteins as Biomarkers for Prostate Cancer


Opko Health said this week it has acquired an exclusive license from Finnish biotech firm Artic Partners for two biomarkers from the kallikrein protein family that could be used to diagnose prostate cancer.

The biomarkers were identified by researchers at Sweden's University of Malmo, Finland's University of Turku, and New York's Memorial Sloan Kettering Cancer Center, who showed that the markers, in combination with prostate specific antigen, could predict initial biopsy results in men suspected of having prostate cancer.

The researchers tested the markers in more than 8,000 men, and the markers were independently validated in the European Randomized Study of Prostate Cancer Screening.

Although PSA is commonly used as a prostate cancer biomarker, it is not specific for the disease, leading to an estimated 750,000 unnecessary prostate biopsies in the US annually. The Opko test will combine PSA with the two kallikrein markers "to provide significantly greater accuracy," the company said in a statement.

A study published in BMC Medicine in 2008 showed that the addition of the markers improved the predictive value of a standard clinical prostate cancer exam – consisting of age, PSA measurement and a digital rectal exam – to an area under the curve of .84 from an AUC of .72.

"These two new biomarkers provide us with a unique opportunity to greatly improve the value of prostate cancer screening. The higher specificity of our new panel of markers will provide better and more efficient outcomes, while lowering overall costs," Phillip Frost, Opko's chairman and CEO, said in a statement.

"I believe this novel panel of kallikrein biomarkers will help us to greatly reduce the number of unnecessary prostate biopsies performed with their attendant side effects and added costs," added Peter Scardino, chief of surgery at MSKCC and one of the investigators who identified the markers. "I believe this panel of tests will eventually replace PSA measures alone for the early detection of prostate cancer that needs to be treated, helping us to avoid dealing with small, indolent cancers that should be left alone."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.